跳到正文
11月7日周六
11月6日周五
  1. EMA · What's New

    感染病学:Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 64, Status: Authorised

    原文摘录:Comirnaty RSS Authorised This medicine is authorised for use in the European Union COVID-19 mRNA vaccine Medicine Human Authorised Rolling review Application under evaluation CHMP opinion European Commission decision Overview Comirnaty is a vaccine for pr … 5-containing Covid-19 mRNA vaccines in the Nordic countries - post-authorisation study A Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Recipients of the Pfizer-BioNTech COVID-19 mRNA vaccine in the EU - post-authorisation study Real-world effectiveness of different COVID-19 vaccines in Spain: a cohort study based on public electronic health records (BIFAP) (effectiveness of COVID-19 vaccines in Spain) - post-authorisation study This page was last updated on 06/11/2026

11月4日周三
  1. WHO · Official News OData

    WHO建议ChAdOx1与mRNA-1469加入刚果(金)Tumaini试验,Bundibugyo病毒疫苗首次于疫情期间接受临床评估

    WHO候选疫苗优先技术咨询小组基于现有临床前和早期临床证据,建议将牛津大学与印度血清研究所的ChAdOx1及Moderna的mRNA-1469加入刚果(金)Tumaini试验,系针对Bundibugyo病毒的疫苗首次在疫情期间接受临床评估,待国家批准后入组。

    关注理由:针对Bundibugyo病毒的候选疫苗首次在疫情期间进入临床评估,Tumaini多疫苗试验与治疗研究并行推进,结果时间表明确,可跟踪疫情期间疫苗评价模式的验证进展。